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BACKGROUND: A limited number of studies have used Tissue Doppler Imaging (TDI) to evaluate the effect of statin
therapy on left ventricular dysfunction in patients with chronic heart failure. In this work, we aimed to determine
whether statin administration influenced prognosis, inflammatory activation and myocardial performance
evaluated by Tissue Doppler Imaging in subjects enrolled in the Daunia Heart Failure Registry, a local registry of
patients with chronic heart failure.
METHODS: This study retrospectively analyzed 353 consecutive outpatients with chronic heart failure (mean follow-
up 384 days), based on whether statin therapy was used. In all patients, several Tissue Doppler Imaging parameters
were measured; circulating levels of interleukin (IL)-6, IL-10 and C-reactive protein were also assayed.
RESULTS: Statin administration in 128 subjects with ischemic heart disease was associated with a lower incidence of
adverse events (rehospitalization for HF 15% vs. 46%, p,0.001; ventricular arrhythmias 5% vs. 21%, p,0.01; cardiac
death 1% vs. 8%, p,0.05), lower circulating levels of IL-6 (p,0.05) and IL-10 (p,0.01), lower rates of chronic heart
failure (p,0.001) and better Tissue Doppler Imaging performance (E/E’ ratio 12.82¡5.42 vs. 19.85¡9.14, p,0.001;
ET: 260.62¡44.16 vs. 227.11¡37.58 ms, p,0.05; TP: 176.79¡49.93 vs. 136.7¡37.78 ms, p,0.05 and St: 352.35¡43.17
vs. 310.67¡66.46¡37.78 ms, p,0.05).
CONCLUSIONS: Chronic ischemic heart failure outpatients undergoing statin treatment had fewer readmissions for
adverse events, blunted inflammatory activation and improved left ventricular performance assessed by Tissue
Doppler Imaging.
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INTRODUCTION
Chronic heart failure (CHF) is almost always character-
ized by impaired systolic and diastolic function and
increased inflammatory activation. In addition, the inflam-
matory activation depends on the type of initial insult
sustained by the myocardium. The increased production of
pro-inflammatory cytokines, including TNF-alpha, interleu-
kin (IL)-6, IL-1, and IL-18, jeopardizes the surrounding
tissue through the propagation of the inflammatory
response and by directly affecting the cardiac myocyte
structure and function. Cardiac myocyte hypertrophy,
contractile dysfunction, cardiac myocyte apoptosis, and
extracellular matrix remodeling contribute enormously to
the development and progression of CHF.
1
Left ventricular (LV) performance may be assessed by
several methods. Tissue Doppler Imaging (TDI), a newly
developed echocardiographic tool, quantitatively assesses
LV systolic and diastolic function. TDI can be used to
measure systolic time (ST) and ejection time (ST and ET)
intervals in a noninvasive, geometrically independent,
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777easily applicable fashion.
2 Few researchers, however, have
evaluated these intervals in CHF patients.
3,4
Observational studies,
5,6,7 prospective studies,
7-8 and
post-hoc analyses
9-10 of randomized clinical trials have
suggested that statins could be beneficial in patients with
CHF, although the mechanisms in CHF patients are still not
completely known. Small prospective clinical studies using
atorvastatin and simvastatin for systolic heart failure (HF)
have documented an improved LV systolic function and
decreased inflammatory biomarker levels after statin
therapy.
11
A limited number of studies have evaluated the effect of
statin therapy on LV dysfunction in patients with CHF,
particularly using TDI. We therefore aimed to determine
whether statin administration would influence prognosis,
myocardial performance evaluated by TDI and inflamma-
tory activation in subjects with CHF enrolled in the Daunia
Heart Failure Registry.
METHODS
Between January 1, 2008 and June 1, 2010, a total of 353
consecutive patients with CHF were enrolled in the Daunia
Heart Failure Registry; their clinical characteristics are given
in Table I. Each patient’s medical history, heart rate, systolic
blood pressure, body mass index, NYHA class, and
medications were recorded. All patients underwent con-
ventional 2D and TDI echocardiography in an ambulatory
setting and under resting conditions. Clinical follow-up was
performed every 6 months, for a mean of 384¡254 days of
follow-up. Clinical follow-up was anticipated in cases of
worsening decompensated heart failure. Patients were
retrospectively analyzed according to the presence of statin
therapy (N=224, 63.6% of the study population) and the
presence of coronary heart disease (158 patients with a
history of previous myocardial infarction, known coronary
artery disease, prior percutaneous coronary interventions
[PCIs] and coronary artery bypass grafting [CABG]). Of 158
ischemic subjects, 128 were treated with statins. The
incidence of major adverse cardiac events (e.g., cardiac
death, readmission for HF and ventricular arrhythmias) was
evaluated by direct clinical examination or by direct
interrogation of the patient’s relatives. Cardiac death was
considered in cases of sudden death or death associated
with documented myocardial infarction, congestive HF or
malignant ventricular arrhythmias.
Table I - Clinical characteristics.
All Patients N=353 Statin N=224 Controls N=129 CAD Statin N=128 Controls N=30
Mean Std. Dev. Mean Std. Dev. Mean Std. Dev. p Mean Std. Dev. Mean Std. Dev. p
age 66.0 12.2 67.0 10.4 64.1 14.7 ,0.05 67.5 9.2 68.4 13.1 n.s
male gender 69.52% 70.37 % 70.16 % n.s 84.68 % 80.77 % n.s.
BMI 29.5 5.0 29.9 4.4 28.9 6.0 n.s. 29.2 4.2 28.2 4.2 n.s.
SAP 126.5 24.5 126.4 25.3 126.3 23.5 n.s. 124.7 25.6 122.2 22.7 n.s.
hypertension 68.62 % 75.23 % 56.30 % ,0.001 72.73 % 69.23 % n.s
COPD 52.23 % 56.19 % 45.45 % n.s. 56.78 % 61.54 % n.s.
diabetes 31.45 % 36.19 % 22.60 % ,0.05 36.75 % 32 % n.s
renal failure 28.57 % 31.37 % 22.88 % n.s 36.28 % 33.33 % n.s.
creatinine 1.5 0.6 0.3 0.5 0.2 0.4 n.s. 1.5 0.6 1.6 0.5 n.s
Hb 12.6 2.0 12.7 1.9 12.6 2.1 n.s. 13.0 2.0 12.7 2.3 n.s.
ischemic heart disease 45.19 % 57.41 % 21.67 % ,0.001 100 % 100 % n.s.
NYHA III/IV 53.08% 49.53 % 58.68% n.s. 57.38% 92.31% ,0.01
total cholesterol 179.13 42.50 164.11 45.25 173.00 45.53 n.s. 141.33 37.90 133.00 0.00 n.s.
triglycerides 118.31 36.85 131.29 23.78 97.80 48.69 n.s. 122.00 36.77 48.00 0.00 n.s
glycemia 152.15 81.53 147.14 101.12 147.20 80.29 n.s. 215.00 136.30 159.50 45.96 n.s.
atrial fibrillation 19.19 % 14.55 % 25.81 % ,0.05 10.74 % 42.13 % ,0.001
QRS duration 86.9 36.6 88.6 37.3 86.1 35.4 n.s. 85.2 37.5 88.4 36.2 n.s.
LBBB 19.10 % 18.27 % 21.49 % n.s. 14.88 % 20.00 % n.s.
ICD 17.91 % 17.54 % 19.33 % n.s. 23.33 % 34.62 % n.s.
CRT 3.80 % 4.67 % 2.46 % n.s. 4.96 % 0.00 % n.s.
statin 63.64 %
omega 3 18.45 % 26.51 % 4.20 % ,0.001 35.77 % 3.85 % ,0.01
ACE – I 45.35 % 48.36 % 39.63 % n.s. 59.17 % 53.85 % n.s.
ARB 30.21 % 33.49 % 24.17 % n.s. 21.67 % 7.69 % n.s.
BB 71.18 % 75.93 % 63.11 % ,0.05 78.05 % 80.77 % n.s.
CCB 18.13 % 21.05 % 13.33 % n.s. 13.22 % 3.85 % n.s.
aspirin 56.38 % 59.62 % 50.41 % n.s. 72.95 % 50.00 % ,0.05
clopidogrel 18.81 % 27.70 % 2.52 % ,0.001 47.54 % 3.85 % ,0.001
OAT 25.82 % 25.82 % 25.62 % n.s. 14.75 % 34.62 % ,0.05
diuretics 79.71 % 83.80 % 72.95 % ,0.05 82.11 % 92.31 % n.s.
loop diuretics 77.17 % 80.20 % 71.30 % n.s. 83.19 % 95.88 % n.s.
spironolactone 39.52 % 40.74 % 37.93 % n.s. 43.09 % 66.67 % ,0.05
VO2 max 13.49 4.35 13.39 4.03 13.92 4.88 n.s. 14.07 4.44 14.45 4.31 n.s.
AT 0.92 0.74 0.85 0.28 1.06 1.20 n.s. 0.91 0.28 0.80 0.17 n.s.
6 – MWT 321.27 103.19 221.00 50.95 378.57 76.91 ,0.01 226.00 87.68 345.00 0.00 n.s.
CRP 10.36 21.22 6.73 13.02 14.49 29.41 n.s. 9.68 17.59 112.00 0.00 ,0.001
BNP 285.87 484.52 185.76 273.16 390.35 584.82 ,0.05 240.17 367.93 364.25 302.32 n.s.
IL – 6 9.95 22.27 7.87 15.44 15.71 35.74 n.s. 9.47 21.07 61.43 74.40 ,0.05
IL – 10 0.91 2.67 0.57 2.09 0.88 2.55 n.s. 0.65 2.00 5.00 4.58 ,0.01
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778All patients provided informed consent. This study was
approved by the Ethics Committee of University of Foggia
according the ethical standards for experiments in human
subjects established by the Declaration of Helsinki.
Inflammatory markers. Circulating levels of IL-6 and IL-
10 were evaluated in all patients using a commercially
available solid-phase, enzyme-labeled, chemiluminescent
sequential immunometric assay (Immulite 1000 system,
Siemens). The components of this system were a matched
pair of beads: one coated with a monoclonal murine anti-IL-
6 antibody and one coated with the equivalent anti-IL-10
antibody. Biochemical levels were measured using optimal
concentrations of standards and antibodies according to the
manufacturer’s instructions. Incubation cycles were either
twice for 30 minutes (IL-6) or once for 60 minutes.
The concentration of CRP was determined using a
particle-enhanced turbidimetric immunoassay with an
assay range of 0.2 to 12 mg/dl (The Dimension Flex
Immunoassay System, Dade Behring, Inc., IL, USA).
Echocardiography. Conventional echocardiography was
used to assess LV dimensions and ejection fraction (EF),
peak velocities of transmitral early (E) and late diastolic (A)
LV (left ventricle) filling, the ratio of transmitral early to late
LV filling velocity (E/A ratio), and E-deceleration time
(EDT). TDI measurements recorded at the mitral annulus in
the apical four-chamber view included systolic velocity (S’),
early (E’) and late (A’) diastolic velocities, and the ratio of
early to late diastolic velocity (E’/A’). The transmitral to
mitral annular early diastolic velocity ratio (E/E’) was also
calculated (Figure 1).
The time to regional peak systolic velocity (TP: the
beginning of the QRS complex was used as the reference
point), St (the end of the A’ wave to the end of the S wave)
and ET (the start to the end of the S wave) were also
measured by TDI (Figure 1).
Transthoracic echocardiography was performed using
iE33 (Philips Medical Systems, Andover, MA, USA). All
echocardiographic studies were performed and interpreted
by experienced physicians. The LV dimensions and LVEF
were calculated using recommendations from the combined
ASE/ESC guidelines. The LVEF was calculated according to
Simpson’s rule. Pulsed Doppler mitral inflow velocities
were obtained by placing a 1- to 2-mm sample volume
between the tips of the mitral leaflets in the apical four-
chamber view. The Doppler beam was aligned parallel to
the direction of flow.
TDI was performed using apical views for the long-axis
motion of the ventricles, as previously described.
12 Two-
dimensional echocardiography with TDI color imaging was
performed using an S5-1 Sector Array Transducer with
PureWave Crystal Technology (5 to 1 MHz). Two-dimen-
sional echocardiography with TDI color imaging views was
optimized for pulse repetition frequency, color saturation,
sector size, and depth and was allowed the highest possible
frame rate. At least 3 consecutive beats were stored, and the
images were analyzed offline with the aid of a customized
software package (QLAB quantification software, Philips).
The peak myocardial velocity during the ejection phase (S’)
and the time to peak Sm (TP) were measured with reference
to the QRS complex.
STATISTICAL ANALYSES
Continuous variables are expressed as mean¡standard
deviation; categorical variables are presented as percen-
tages. Mean values were compared using Student’s t-test for
variables with a normal distribution or using the Mann-
Whitney U non-parametric test for non-normally distribu-
ted variables. Percentages were compared using a x
2 test.
Event-free survival was shown with Kaplan-Meier curves
Figure 1 - (upper left panel) TDI parameters: systolic velocity (S’), early (E’) and late (A’) diastolic velocities. (Lower right panel) PW-
Doppler transmitral velocities: peak velocities of transmitral early (E) and late diastolic (A) LV filling. The transmitral to mitral annular
early diastolic velocity ratio (E/E’) was calculated. (Right panel) time to regional peak systolic velocity (TP: the beginning of the QRS
complex was used as the reference point), systolic time (St: the end of the A’ wave to the end of the S wave) and ejection time (ET: the
start of the S wave to the end of the S wave).
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779and compared using the log-rank test. Univariate results
were adjusted in a multivariate analysis for age, gender, LV
ejection fraction (LVEF) and other significant factors
according to a Cox regression analysis. A p,0.05 was
considered to be statistically significant.
RESULTS
353 patients were enrolled in the registry; 224 (63%) were
treated with statins. A total of 77.3% (N=172) were treated
with atorvastatin (mean daily dose 30.2¡16.3 mg), 2.3%
(N=4) with pravastatin (mean daily dose 26.7¡10.3 mg),
15.7% (N=33) with simvastatin (mean daily dose
19.7¡6.3 mg), 4.2% (N=14) with rosuvastatin (mean daily
dose 10.6¡3.9 mg), and 0.5% (N=1) with fluvastatin. In the
subgroup of patients with ischemic heart disease (N=158,
45%), 128 were treated with statins: 79% (N=101) were
treated with atorvastatin (mean daily dose 35.3¡18.1 mg),
2% (N=2) with pravastatin (mean daily dose 30.0¡14.1 mg),
16.9% (N=22) with simvastatin (mean daily dose
19.5¡8.0 mg), and 2.4% (N=3) with rosuvastatin (mean
daily dose 13.3¡5.8 mg).
In a retrospective, non-randomized analysis, therapy with
statinswasassociatedwitha lower incidenceof cardiac death
(1% vs. 5%, p,0.05) (Table II). The association remained
statisticallysignificanteven aftercorrectionina multivariable
analysis for age, gender, LVEF, cholesterol levels, and
therapy with ACE inhibitors and beta blockers. No correla-
tion was seen between statin dose and outcome at follow-up.
Patients prescribed statins exhibited lower values of E/A
(1.53¡0.79 vs. 1.95¡0.86, p,0.001) and E/E’ (13.71¡5.88
vs. 16.28¡8.69, p,0.01), as well as higher values of EDT
(220.17¡89.58 vs. 187.38¡84.95 ms, p,0.01) (Table III).
In a subgroup analysis of 150 patients with ischemic HF,
those receiving therapy with statins showed a lower
incidence of readmissions for worsening HF (15% vs. 46%,
p,0.001), ventricular arrhythmias (5% vs. 21%, p,0.01),
and cardiac death (1% vs. 8%, p,0.05) (Table II); lower
circulating levels of inflammatory markers (IL-6: 9.47¡21.06
vs. 61.43¡74.39 pg/ml, p,0.05; IL-10: 0.65¡1.99 vs.
5.0¡4.58 pg/ml, p,0.01; and CRP: 9.68¡17.59 vs. 112 mg/
dl, p,0.001); a lower E/E’ ratio (12.82¡5.42 vs. 19.85¡9.14,
p,0.001); longer systolic time intervals (ET: 260.62¡44.16
vs. 227.11¡37.58 ms, p,0.05 and St 352.35¡43.17 vs.
310.67¡66.46¡37.78 ms, p,0.05); a higher value of TP
(176.79¡49.93 vs. 136.7¡37.78 ms, p,0.05); a lower E/A
ratio (1.48¡0.79 vs. 2.33¡0.85, p,0.001); and a higher EDT
(230.75¡89.67 vs. 166.98¡70.52 ms, p,0.01) (Table III).
Episodes of decompensated HF requiring rehospitaliza-
tion were related to E (odds ratio [OR] 1.33, 95% confidence
interval [CI] 1.11-1.59, p,0.01); A (OR 0.81, 95% CI 0.65-0.99,
p,0.05); E/A (OR 1.37, 95% CI 1.16-1.63, p,0.001); EDT
(OR 0.72, 95% CI 0.60-0.87, p,0.001); E/E’ (OR 1.46, 95% CI
1.23-1.74, p,0.001); S (OR 0.78, 95% CI 0.65-0.94, p,0.01); E’
(OR 0.85, 95% CI 0.71-1.01, p=0.07); and A’ (OR 0.82, 95% CI
0.67-1.01, p=0.06). Using multivariable analysis correlation,
only E/E’ (p,0.01) remained significant.
Kaplan-Meier survival analysis showeda poorer prognosis
in subjects not receiving statin therapy (log-rank p,0.01),
with higher rates of rehospitalization for decompensated HF
(Figure2).UsingmultivariateCoxregressionanalysis,higher
readmission rates in subjects not receiving statins were
independent of age, gender, LVEF, NYHA class, cholesterol
levels, presence of atrial fibrillation, or concomitant therapy
with ACE inhibitors, beta blockers, v3 fatty acids, clopido-
grel, aspirin or spironolactone (p,0.01) (Figure 3).
DISCUSSION
Several observational studies of HF cohorts have linked
statin therapy to an improved survival rate.
10-15 However,
the beneficial mechanisms have not been completely
established. Small, prospective clinical studies on atorvas-
tatin and simvastatin in systolic HF have documented an
improved ventricular systolic function and decreased levels
of inflammatory biomarkers after statin therapy.
29,13
Previous evidence has shown that, in patients with prior
myocardial infarction, statin therapy initiated prior to
hospital discharge significantly reduced subsequent hospi-
talizations for HF;
14 furthermore, the initiation and main-
tenance of treatment with statins has been associated with
better survival in patients with LV systolic dysfunction.
15 In
a recent report, Sankaranarayanan et al.
16 showed that
mortality in patients with ischemic CHF treated with statins
was significantly lower than in controls. Univariate analysis
also showed fewer HF readmissions (7% vs. 32%) and HF
deaths (4% vs. 13%), with effects independent of cholesterol
levels, age, sex, drugs, revascularization, and implantable
cardioverter-defibrillator or cardiac resynchronization ther-
apy using multivariable analysis.
Our results corroborate the above evidence; therapy with
statins was associated with a lower incidence of cardiac
death, and the association remained significant even after
correction in a multivariable analysis for age, gender, LVEF
and therapy with ACE inhibitors and beta blockers.
Furthermore, ischemic HF patients receiving therapy with
Table II - Clinical outcomes.
All patients N=353 Statin N=224 Controls N=129 CAD Statin N=128 Controls N=30
Mean Std.Dev. Mean Std.Dev. Mean Std.Dev. p Mean Std.Dev. Mean Std.Dev. p
MACE 39.32 % 38.25 % 40.65 % n.s. 39.52 % 53.85 % n.s.
AMI 1.74 % 2.34 % 0.00 % n.s. 2.46 % 0.00 % n.s.
cardiac death 2.62 % 0.93 % 4.96 % ,0.05 0.82 % 8.33 % ,0.05
urgent
revascularization
0.58% 0.47 % 0.83 % n.s. 0.82 % 4.17 % n.s.
ventricular
arrhythmias
6.71 % 5.16 % 9.92 % n.s. 4.96 % 20.83 % ,0.01
any re-
hospitalization
21.51 % 23.38 % 18.18 % n.s. 21.31 % 20.83 % n.s.
re-hospitaliz. for HF 15.99 % 14.02 % 20.66 % n.s. 14.75 % 45.83 % ,0.001
death 8.75 % 7.01 % 10.00 % n.s. 5.74 % 17.39 % 0.053
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780statins showed a lower incidence of readmissions for
worsening HF. In a multivariate Cox regression analysis,
higher readmission rates in subjects not receiving statins
were independent of age, gender, LVEF, and concomitant
therapy with ACE inhibitors and beta blockers.
In previous research, statins have appeared to provide
similar benefits to patients with non-ischemic and ischemic
cardiomyopathy;
17 our results, however, suggest a wider
benefit of statin therapy in patients with coronary heart
disease. In fact, those receiving therapy with statins, in
addition to a lower incidence of readmissions for worsening
HF, also demonstrated a lower incidence of cardiac deaths
(1% vs. 8%) and ventricular arrhythmias (5% vs. 21%).
Previous studies have shown that non-antiarrhythmic
drugs, such as those acting on the renin-angiotensin-
aldosterone system, fish oil, and statins, can reduce the
likelihood of future ventricular tachycardia/ventricular
fibrillation in patients with coronary artery disease or
congestive HF.
18 In our study, among patients with ischemic
HF, those receiving therapy with statins showed a lower
incidence of ventricular arrhythmias than controls.
The mechanisms by which statins exert their positive
effects are not completely known. In our study, statin
administration was related to a better LV performance as
measured by TDI. There is evidence that abnormal para-
meters identified by TDI can identify subjects at risk for
Table III - Echocardiographic characteristics.
All patients N=353 Statin N=224 Controls N=129 CAD Statin N=128 Controls N=30
Mean Std. Dev. Mean Std. Dev. Mean Std. Dev. p Mean Std. Dev. Mean Std. Dev. p
LVEF 40.41 13.30 39.78 12.63 41.11 14.46 n.s. 39.06 11.40 33.46 12.46 ,0.05
LVEDD 57.00 10.95 56.67 10.13 57.96 12.22 n.s. 57.28 9.17 59.63 10.08 n.s
LVESD 47.99 12.27 47.67 11.94 49.03 12.83 n.s. 48.75 10.42 54.38 9.27 n.s.
E 89.45 35.43 93.39 32.26 98.35 36.16 ,0.001 76.15 28.13 112.21 34.96 ,0.001
A 85.04 29.61 86.68 25.62 80.67 36.90 n.s. 87.26 24.12 75.67 38.19 n.s.
E/A 1.68 0.84 1.54 0.79 1.95 0.86 ,0.001 1.48 0.79 2.33 0.86 ,0.001
EDT 208.04 89.01 220.17 89.58 187.38 84.95 ,0.01 230.75 89.68 166.98 70.53 ,0.01
E/E’ 14.62 7.15 13.71 5.88 16.28 8.69 ,0.01 12.82 5.42 19.85 9.14 ,0.001
S’ 5.98 1.76 5.96 1.74 5.97 1.82 n.s. 5.98 1.89 5.25 1.88 n.s.
E’ 6.95 3.01 6.85 2.97 7.04 3.02 n.s. 6.68 2.53 6.14 2.45 n.s.
A’ 8.14 2.76 8.17 2.61 8.04 3.08 n.s. 8.47 2.81 5.88 2.82 ,0.01
ET 265.53 48.47 264.08 45.32 267.29 54.24 n.s. 260.62 44.17 227.11 37.58 ,0.05
St 360.80 55.95 361.45 49.64 359.35 66.24 n.s. 352.35 43.17 310.67 66.40 ,0.05
TP 179.26 61.40 182.00 54.12 175.92 73.58 n.s. 176.79 49.94 136.57 37.78 ,0.05
Figure 2 - Kaplan-Meier analysis showing a poorer prognosis (lower rates of readmission for decompensated heart failure) in subjects
not receiving therapy with statins (log-rank p,0.01).
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781adverse events in major cardiac diseases, such as HF. In
particular, patients with reduced S’ or E’ values of ,3 cm/s
have an extremely poor prognosis. During HF and after
myocardial infarction, non-invasive assessment of LV
diastolic pressure by transmitral to mitral annular early
diastolic velocity ratio (E/E’) is a strong predictor of
prognosis, especially when E/E’ is $15. Several researchers
have assessed the effect of statin therapy on LV function by
TDI and showed that compared with baseline, S’ and E’
increased significantly after atorvastatin therapy in patients
with coronary artery disease.
19 In our study, HF patients
administrated statins had lower values of E/A and E/E’
and higher values of EDT. Furthermore, we saw lower
values of the E/E’ ratio and higher EDT, suggesting a minor
grade of diastolic dysfunction, in ischemic CHF patients
receiving therapy with statins. In addition, TDI can be used
to measure ST and ET intervals in a noninvasive, geome-
trically independent, easily applicable fashion.
14-19 Few
authors have evaluated these intervals in CHF patients;
Reant P et al.
8 showed that ST intervals could be used to
detect alterations in LV systolic function. Chen HM et al.
determined the cutoff values for ET in predicting high N-
terminal pro-brain natriuretic peptide (NT-proBNP) levels.
9
To our knowledge, there have been no previous studies
evaluating the effect of statin therapy on ST intervals
detected by TDI. In the present work, we showed higher
values of ET and ST in ischemic CHF patients receiving
therapy with statins. Therefore, lower values of ST intervals,
as for ET, in patients not receiving statin therapy also
suggest a higher grade of LV diastolic dysfunction, as
previously demonstrated by Jarnert et al.
20 In statin therapy
patients, we were also able to show a smaller grade of
diastolic dysfunction than in controls by conventional
Doppler (E/A and EDT), TDI (E/E’) and longer systolic
intervals (ST and ET). In addition to lipid-lowering and anti-
atherosclerotic effects, statins have demonstrated other non-
lipid related or pleiotropic effects that could be beneficial in
HF. Statins may inhibit or reverse myocardial remodeling,
21-22
inhibit inflammation in HF, improve endothelial function,
11,23,24
and restore autonomic nervous system balance.
25 Furthermore,
Figure 3 - After multivariate Cox regression analysis, higher readmission rates in subjects not receiving statins were independent of age,
gender, LVEF, and concomitant therapy with ACE inhibitors and beta blockers (p,0.01).
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782statin treatment may lower inflammatory activation in several
cardiac diseases. ‘‘Increased circulating and intra-cardiac
levels of pro-inflammatory cytokines have been associated
with CHF. Following an initial insult, the increased produc-
tion of pro-inflammatory cytokines, including TNF-alpha, IL-
6, IL-1, and IL-18, jeopardizes the surrounding tissue through
propagation of the inflammatory response and direct effects
on the cardiac myocyte structure and function. Cardiac
myocyte hypertrophy, contractile dysfunction, cardiac myo-
cyte apoptosis, and extracellular matrix remodeling contri-
bute enormously to the development and progression of
CHF’’.
1 Previous authors have shown that atorvastatin
treatment may induce a significant decrease in the activity
of matrix metalloproteinase-9, high-sensitivity CRP, TNF-
alpha, IL-6, and malondialdehyde, and a significant increase
in endothelial superoxide dismutase activity compared with
the placebo. In CHF patients, atorvastatin therapy has been
associated with a decrease in inflammation (as measured by
IL-6 and CRP levels) and extracellular matrix remodeling,
improving both endothelial function and exercise capacity.
26
Atorvastatin treatment significantly decreased the concentra-
tionof IL-6in patients withdilated cardiomyopathy after two
months of therapy.
27,28 Recently, Amir et al.
29 showed that
elevated circulating IL-10 levels in systolic HF patients did
not have a protective counterbalance effect on mortality. In
addition,Wanget al.
30 demonstratedthat plasmalevelsof IL-
10 were higher in HF patients than controls. In contrast, other
studies
31 have shown a better event-free survival rate with
higher IL-10 levels in hospitalized CHF patients. In a
retrospective analysis, the authors found a significant
interaction between hs-CRP and the effect of rosuvastatin
for most end points whereby rosuvastatin treatment was
associated with better outcomes in patients with hs-CRP
$2.0 mg/L.
32 In addition, Liu et al.
33 have shown that twelve
weeks of treatment with atorvastatin (10 mg/day) signifi-
cantly decreased serum CRP.
Our findings appear to confirm these previous results; in
ischemic CHF patients receiving statin therapy, circulating
levels of the inflammatory markers IL-6, IL-10 and CRP
were significantly lower, thus supporting an additional
hypothesis for the mechanism of the better outcomes seen in
HF patients. It still remains not completely clear whether
statin administration improves LV performance (evaluated
in our study by TDI) through reducing inflammatory
activation featuring LV dysfunction or blunted inflamma-
tory activation associated with statin therapy may some-
times positively affect LV performance.
LIMITATIONS
These are preliminary data from a non-randomized
observational registry with a limited number of patients.
Statin administration depended on clinician judgment.
Further,randomizedtrials are needed to confirm these results.
CONCLUSIONS
Ischemic outpatients with CHF undergoing statin treat-
ment showed fewer readmissions, a blunted inflammatory
activation and a better LV performance as assessed by TDI.
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